The UK’s price watchdog is backing coverage for Pfizer’s Bosulif at a new discounted price, broadening access to the drug that was previously only available through the now-revamped Cancer Drugs Fund.
Source: Drug Industry Daily
The UK’s price watchdog is backing coverage for Pfizer’s Bosulif at a new discounted price, broadening access to the drug that was previously only available through the now-revamped Cancer Drugs Fund.
Source: Drug Industry Daily